PP
ALXO icon

PDT Partners’s ALX Oncology ALXO Stock Holding History

PDT Partners’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-21,735
Closed -$245K – 563
2022
Q4 		$245K Sell
21,735
-14,635
-40% -$164K 0.04% 517
2022
Q3 		$348K Sell
36,370
-66,326
-65% -$773K 0.05% 538
2022
Q2 		$831K Buy
+102,696
New +$1.12M 0.07% 453
2022
Q1 		– Sell
-15,154
Closed -$326K – 920
2021
Q4 		$326K Buy
+15,154
New +$654K 0.02% 648

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

PDT Partners's ALXO Position: Q1 2023 in Review

PDT Partners sold out of ALX Oncology (ALXO) in Q1 2023, closing a stake of 21,735 shares — an estimated $245K sold.

PDT Partners first reported a position in ALXO in Q4 2021 and held it in 4 quarters. The position peaked at $831K in Q2 2022. 86 funds tracked by Wall St. Rank hold ALXO as of Q1 2023.

  • PDT Partners reported no remaining ALX Oncology position as of Q1 2023 after selling out during the quarter.
  • PDT Partners sold 21,735 ALX Oncology shares in Q1 2023, an estimated $245K.
  • PDT Partners first reported a position in ALX Oncology in Q4 2021 and held it in 4 quarters.
  • PDT Partners's ALX Oncology position peaked at $831K in Q2 2022.
  • 86 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2023.

Based on PDT Partners's 13F filing for Q1 2023, filed 15 May 2023.